youtube_live
Q3 2026 earnings • in 2 days
See detailschevron_right
NBIX:NASDAQ
Neurocrine Biosciences, Inc
$146.10
arrow_downward
-0.19%(-0.28) 1D
$146.10
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 30, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NBIX...
Open
$147.13
High
$149.25
Low
$145.22
Mkt. cap
14.85B
Avg. vol.
1.37M
Volume
1.32M
P/E ratio
21.42
52-wk high
$186.12
52-wk low
$122.14
EPS
$6.82
Beta
0.40
Shares outstanding
101.65M
No. of employees
2K
Open
$147.13
High
$149.25
Low
$145.22
Mkt. cap
14.85B
Avg. vol.
1.37M
Volume
1.32M
P/E ratio
21.42
52-wk high
$186.12
52-wk low
$122.14
EPS
$6.82
Beta
0.40
Shares outstanding
101.65M
No. of employees
2K
News stories
From web sources and news partners
Investing.com Nigeria
·
10 hours ago
Form 144 NEUROCRINE BIOSCIENCES For: 31 October By Investing.com
Profile
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
About Neurocrine Biosciences, Inc
CEOKevin C. Gorman
Employees2.5K
Founded1992
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websiteneurocrine.com